LAS VEGAS—GE HealthCare unveiled its new generative AI platform, CareIntellect, on stage at HLTH 2024 on Monday. The first application available on the platform is for oncology.
CareIntellect will eventually be a suite of clinical and operational AI solutions. GE HealthCare’s goal is to make it easy for a health system to integrate with CareIntellect once, then be able to access a range of solutions for the health system. The platform will be commercially available in 2025 in the U.S.
The flexible platform will also make it easy for clinicians to experiment with new applications through the ability to easily turn on new solutions for certain clinicians and scale up or down the number of people who have access.
“We've designed CareIntellect so that you will not have to invest significant time and resources on integrating and maintaining applications,” Taha Kass-Hout, M.D., chief science and technology officer at GE HealthCare, said in a keynote. “To put this simply, think about the smartphone in your pocket. Think about how you can use a wide variety of applications on your phones, tablets or computers with a single login. That's a lot like how CareIntellect works,” he said.
Parminder Bhatia, chief AI officer of GE HealthCare, told Fierce Healthcare that 97% of patient data go unutilized. CareIntellect is a cloud-first suite of gen AI solutions that could tap into some of these data and make sense of the information.
CareIntellect aggregates and summarizes multimodal data. CareIntellect for Oncology could help clinicians at the point of care through clinical note summarization and delving through what treatments patients have had in the past.
The platform is built on open data standards which help GE HealthCare integrate with health systems’ data.
CareIntellect for Oncology will be tested at two health systems, UT Southwestern and Tampa General. UT Southwestern will use the application for prostate cancer patients.
When GE HealthCare began talks with Tampa General, it was interested in deploying CareIntellect Oncology for breast cancer. Bhatia said that within a few weeks, GE was able to adapt the model for breast cancer. He also said the model could potentially be adapted to work in cardiology and neurology.
CareIntellect Oncology can also assist clinicians with clinical trial matching and includes suggestions to boost eligibility for clinical trials.
GE HealthCare intends to build more solutions that will become available on the CareIntellect platform. Bhatia said that it also may be able to offer the AI solutions of GE partners.
Kass-Hout also floated a solution in progress called Health Companion, a team of AI agents that could dive deep into separate parts of the patient record like clinical, biochemical and radiological data. A “supervising” agent would then summarize the outputs from the individual AI agents and create a care plan for the clinician.
The clinician would be able to give feedback to the AI agents on the care plan and the AI could continue learning from correction and interaction by the clinician.
Kass-Hout said that the Health Companion could be especially useful to look into a patient’s history. He gave the example of a patient who has been living with prostate cancer for eight years. The patient would have generated thousands of medical data points. The AI agents would be able to comb through the data to determine the disease progression and the optimal care plan.
“This AI team is much like a multidisciplinary tumor group that evaluates evidence of metastatic spread,” Kass-Hout said.
Health Companion could eventually become a part of CareIntellect, Bhatia said, but it is still in the early stages of development.
“Our vision is for an interconnected, intelligent ecosystem that not only streamlines the patient journey, but leverages analytics and proactive interventions to elevate the standard of care,” Kass-Hout said.
Editor's note: A previous version of this article misidentified how much patient data goes unutilized. The story has been updated to reflect that GE HealthCare has not yet deployed CareIntellect at UT Southwestern and Tampa General.